Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.

Ítems similars

• Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
  per: Lissoni, P., et al.
  Publicat: (1989)
• Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
  per: Lissoni, P., et al.
  Publicat: (1991)
• A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
  per: Lissoni, P., et al.
  Publicat: (1994)
• Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
  per: Lissoni, P., et al.
  Publicat: (1993)
• Pretreatment serum markers and lymphocyte response to interleukin-2 therapy
  per: Fumagalli, L, et al.
  Publicat: (1999)